Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccine
Introgen's INGN 225 molecular cancer vaccine demonstrates promising results
February 27th, 2007
Approximately half of patients with advanced small cell lung cancer responded to Introgen Therapeutics, Inc.'s (INGN) INGN 225 molecular cancer vaccine in combination with subsequent chemotherapy. The encouraging phase II clinical data were presented recently by Introgen's collaborator Scott Antonia of the H. Lee Moffitt Cancer Center & Research Institute. Patients in the study achieved a 52% objective tumor response rate and 41% of patients were still alive 1 year after receiving the immunotherapy. Historically, tumor responses to second-line chemotherapy are between 6-30% and most patients survive for less than 6 months. The data imply that INGN...
Source: Cancer Weekly (2007-02-27)
|
